Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience

Fig. 1

PFS (a) and OS (b) of patients receiving nal-IRI + 5-FU/LV based on prior irinotecan (IRI) based chemotherapy. Patients were classified based on whether their disease had not progressed on prior IRI-based chemotherapy (IRI, no progression), had progressed on prior IRI-based chemotherapy (IRI, progression), or had not received any prior IRI-based chemotherapy (no-IRI)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us